g(m1)-ganglioside and 1-methyl-4-(2--methylphenyl)-1-2-3-6-tetrahydropyridine

g(m1)-ganglioside has been researched along with 1-methyl-4-(2--methylphenyl)-1-2-3-6-tetrahydropyridine* in 2 studies

Other Studies

2 other study(ies) available for g(m1)-ganglioside and 1-methyl-4-(2--methylphenyl)-1-2-3-6-tetrahydropyridine

Article	Year
GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse. Brain research, 1994, Feb-14, Volume: 636, Issue:2 The weaver mutation in the mouse is a developmental disorder characterized by cerebellar atrophy as well as decreased numbers of substantia nigra dopaminergic neurons and a striatal dopamine loss. Since the nigrostriatal dopamine loss occurs postnatally, the present study was performed to determine whether early intervention with GM1 ganglioside could alter the extent of this dopamine loss. Weaver mice that received injections of GM1 ganglioside (30 mg/kg) daily, beginning at 7-10 days of age, had significantly higher striatal dopamine levels and significantly more tyrosine hydroxylase-positive substantia nigra pars compacta neurons than weaver mice that received only daily saline injections. These results show that GM1 treatment can alter at least some aspects of this inherited developmental disorder. If the weaver defect is related to a deprivation of trophic support for certain midbrain dopaminergic neurons, the presence of GM1 may be able to enhance the survival of these neurons. Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Agents; Female; G(M1) Ganglioside; Heterozygote; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Neurologic Mutants; Neostriatum; Neural Pathways; Neurons; Substantia Nigra; Tyrosine 3-Monooxygenase	1994
Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment. European journal of pharmacology, 1990, May-31, Volume: 181, Issue:1-2 After 7 days of treatment with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), 30 mg/kg i.p., tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD) activities are decreased by more than 50% in the mouse striatum. Within 30 days, AAAD activity returns while TH activity remains depressed. TH activity can be restored to near normal by chronic treatment with GM1 ganglioside, 30 mg/kg i.p. Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; G(M1) Ganglioside; Male; Mice; MPTP Poisoning; Nervous System Diseases; Tyrosine 3-Monooxygenase	1990

Article

Year

GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse.

Brain research, 1994, Feb-14, Volume: 636, Issue:2

The weaver mutation in the mouse is a developmental disorder characterized by cerebellar atrophy as well as decreased numbers of substantia nigra dopaminergic neurons and a striatal dopamine loss. Since the nigrostriatal dopamine loss occurs postnatally, the present study was performed to determine whether early intervention with GM1 ganglioside could alter the extent of this dopamine loss. Weaver mice that received injections of GM1 ganglioside (30 mg/kg) daily, beginning at 7-10 days of age, had significantly higher striatal dopamine levels and significantly more tyrosine hydroxylase-positive substantia nigra pars compacta neurons than weaver mice that received only daily saline injections. These results show that GM1 treatment can alter at least some aspects of this inherited developmental disorder. If the weaver defect is related to a deprivation of trophic support for certain midbrain dopaminergic neurons, the presence of GM1 may be able to enhance the survival of these neurons.

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Agents; Female; G(M1) Ganglioside; Heterozygote; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Neurologic Mutants; Neostriatum; Neural Pathways; Neurons; Substantia Nigra; Tyrosine 3-Monooxygenase

1994

Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment.

European journal of pharmacology, 1990, May-31, Volume: 181, Issue:1-2

After 7 days of treatment with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), 30 mg/kg i.p., tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD) activities are decreased by more than 50% in the mouse striatum. Within 30 days, AAAD activity returns while TH activity remains depressed. TH activity can be restored to near normal by chronic treatment with GM1 ganglioside, 30 mg/kg i.p.

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; G(M1) Ganglioside; Male; Mice; MPTP Poisoning; Nervous System Diseases; Tyrosine 3-Monooxygenase

1990